ProShares UltraShort NASDAQ Biotechnology (BIS) seeks to deliver -2x the daily performance of the NASDAQ Biotechnology Index, which tracks approximately 200 biotechnology and pharmaceutical companies listed on NASDAQ. This inverse leveraged ETF profits when biotech stocks decline, making it a bearish bet on the sector.
How It Works
BIS uses derivatives including swaps, futures, and short positions to achieve -200% daily exposure to its benchmark index. The fund rebalances daily to maintain its -2x target, using mathematical formulas to adjust positions based on the previous day's performance. As an actively managed inverse ETF, it doesn't hold biotech stocks directly but instead uses financial instruments that move opposite to the underlying index with double the magnitude.
Key Features
- Provides -2x daily exposure to biotech sector decline, allowing investors to profit from falling pharmaceutical stock prices
- Targets NASDAQ Biotechnology Index covering major biotech names like Gilead, Amgen, and Moderna with precise inverse correlation
- Daily rebalancing ensures consistent -2x exposure but creates compounding effects that deviate from long-term -2x performance
Risks
- This ETF can lose significant value if biotech stocks rise, with losses amplified 2x—a 10% sector gain results in approximately 20% ETF loss
- Daily reset causes compounding decay over time, meaning holding periods beyond days can produce returns dramatically different from -2x the index performance
- Biotech sector volatility can exceed 30-40% annually, creating extreme daily swings that compound unpredictably in this leveraged inverse structure
Who Should Own This
Designed exclusively for sophisticated traders with high risk tolerance and holding periods of hours to days, not weeks or months. Requires active monitoring and represents a tactical short-term bet against biotech sector performance. Should comprise maximum 1-5% of portfolio as a hedging or speculative position only.